Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.

Composite photo of Cambodian people living the the forest, with a photo of a snake and of a pangolin © MORU 2020
An improvised village for forest workers, who sustain themselves with food gathered from the surrounding jungle.

Sponsored by University of Oxford and funded by the Global Fund Regional Component of the Regional Artemisinin-resistance Initiative (RAI2E) Grant, PAL is led by Principal Investigator Prof Richard Maude, with co-investigators MORU’s S. Sovannaroth, Tom Peto, James Callery, Mallika Imwong, Rupam Tripura, Mehul Dhorda, and Lorenz von Seidlein.

An estimated 2,000 participants who travel to the forest and stay overnight will receive either artemether-lumefantrine or multivitamin twice daily for 3 days followed by two doses weekly. They will be followed up every 28 days as they continue to visit the forest. Participants’ travel in the forest will be mapped to identify potential transmission sites and in-depth interviews conducted among forest goers, community leaders, healthcare workers and policymakers in Cambodia, Lao PDR and Thailand to assess the potential feasibility of prophylaxis in each country.

On 10 Feb, MORU and CNM organized an orientation meeting with the Provincial Health Department, Governor Office, local authorities, NGO partners, Village leaders and Village Malaria Workers to inform activities and aim of the PAL-Cambodia project. Following the site Initiation visit and training conducted by MORU’s Epidemiology and CTSG departments, the Cambodia team, led by Dr Rupam Tripura, has conducted engagement activities through schools and meetings with villagers.

Recruitment began on 10 March, and trial participants were given either artemether-lumefantrine or multivitamin and a mobile phone with a GPS logger installed for each group. Participants took pictures and shared some of the images while they stayed in the forest.

- Thank you, Rupam Tripura and James Callery for text and photos.

Similar stories

Congratulations to Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George!

David Warrell, MORU founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allows researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.